\-\ Texto\\:\\ \ \(0\)\
\-\ follow\\-up\\ ct\\ chest\\ in\\ one\\ year\\ to\\ ensure\\ stability\\ or\\ improvement\\.\ \(0\)\
\-\ ct\\ remarkable\\ for\\:\ \(0\)\
\-\ mediastinum\\:\\ noncalcified\\ mediastinal\\ and\\ bilateral\\ hilar\\ lymphadenopathy\\.\\ no\\ cardiac\\ enlargement\\.\\ no\\ pericardial\\ effusion\\.\\ \ \(0\)\
\-\ lungs\\:\\ in\\ the\\ right\\ upper\\ lobe\\ there\\ is\\ a\\ patchy\\ and\\ confluent\\ ground\\-glass\\ density\\ 4\\.6\\ x\\ 3\\.3cm\\ \\(image\\ 27\\)\\ and\\ peribronchovascular\\ interstitial\\ thickening\\ that\\ can\\ be\\ traced\\ from\\ this\\ density\\ to\\ the\\ hila\\ \\(see\\ image\\ 32\\)\\.\\ in\\ both\\ upper\\ and\\ right\\ middle\\ lobes\\ there\\ are\\ areas\\ of\\ ground\\ glass\\ opacity\\ with\\ a\\ peribronchial\\ vascular\\ distribution\\.\ \(0\)\
\-\ chest\\ radiograph\\ remarkable\\ for\\ prominent\\ bilateral\\ hila\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ sarcoidosis\ \(108\)\
\-\ bronchalveolar\\ cell\\ carcinoma\ \(0\)\
\-\ infectious\\,\\ fungal\\ or\\ mycobacterial\ \(0\)\
\-\ lymphoma\\ or\\ malignancy\\ \\(4\\)\ \(0\)\
\-\ langerhans\\ cell\\ histiocytosis\\ \ \(0\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ lymphangitic\\ carcinomatosis\ \(14\)\
\-\ pneumoconiosis\ \(7\)\
\-\ 46\\ year\\ old\\ female\\ presents\\ for\\ follow\\ up\\ ct\\.\\ relatively\\ asymptomatic\\.\ \(0\)\
\-\ discussion\\:\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ the\\ patient\\ came\\ to\\ us\\ with\\ a\\ well\\ established\\ diagnosis\\ of\\ sarcoidosis\\ since\\ 1998\\ \\(8\\ years\\)\\.\\ \\ the\\ patient\\ was\\ followed\\ with\\ chest\\ radiographs\\ until\\ she\\ presented\\ 2\\ years\\ ago\\ with\\ a\\ ct\\ order\\ for\\ \\‚\\Ä\\úseveral\\ abnormal\\ cts\\‚\\Ä\\ù\\ from\\ an\\ outside\\ institution\\.\\ ct\\ with\\ contrast\\ at\\ that\\ time\\ was\\ consistent\\ with\\ stage\\ ii\\ sarcoidosis\\ with\\ enlarged\\ mediastinal\\ and\\ bilateral\\ hilar\\ lymph\\ nodes\\ and\\ areas\\ of\\ parenchymal\\ abnormality\\ with\\ the\\ additional\\ finding\\ suggestive\\ of\\ a\\ superimposed\\ infectious\\ process\\ such\\ as\\ non\\-tuberculous\\ mycobacterial\\ infection\\.\\ 2\\ years\\ ago\\,\\ in\\ the\\ patient\\'s\\ ct\\ scan\\,\\ it\\ was\\ noted\\ in\\ the\\ impression\\ that\\ bronchoalveolar\\ carcinoma\\ or\\ foci\\ of\\ atypical\\ adenomatous\\ hyperplasia\\ was\\ part\\ of\\ the\\ differential\\ because\\ of\\ an\\ increase\\ in\\ diameter\\ of\\ a\\ nodule\\ from\\ 5mm\\ to\\ 10mm\\.\\ since\\ that\\ time\\ the\\ patient\\ has\\ been\\ followed\\ clinically\\ and\\ with\\ ct\\.\\ \\ this\\ ct\\ demonstrated\\ no\\ enlargement\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ the\\ usual\\ indications\\ for\\ lung\\ ct\\ scans\\ are\\ for\\ 1\\)\\ atypical\\ clinical\\ and\\/or\\ chest\\ radiographic\\ findings\\,\\ 2\\)\\ detection\\ of\\ complications\\ of\\ the\\ lung\\ disease\\,\\ such\\ as\\ bronchiectasis\\,\\ aspergilloma\\,\\ pulmonary\\ fibrosis\\,\\ emphysema\\,\\ or\\ a\\ superimposed\\ infection\\ or\\ malignancy\\,\\ 3\\)\\ a\\ normal\\ chest\\ radiograph\\ but\\ a\\ clinical\\ suspicion\\ for\\ sarcoidosis\\ \\(5\\)\\.\\ hrct\\ is\\ not\\ recommended\\ to\\ be\\ performed\\ on\\ all\\ patients\\ with\\ sarcoidosis\\,\\ but\\ it\\ may\\ be\\ helpful\\ for\\ the\\ above\\ reasons\\ and\\ for\\ selected\\ patients\\ with\\ stage\\ ii\\ or\\ iii\\ disease\\ to\\ discriminate\\ active\\ inflammation\\ from\\ irreversible\\ fibrosis\\ \\(5\\)\\.\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ although\\,\\ langerhans\\ cell\\ histiocytosis\\ shares\\ some\\ ct\\ features\\ with\\ sarcodosis\\;\\ bronchial\\ distortion\\,\\ displaced\\ fissures\\,\\ and\\ perihilar\\ predominance\\ are\\ absent\\ in\\ lch\\ \\(5\\)\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ with\\ hypersensitivity\\ pneumonia\\,\\ the\\ features\\ of\\ centrilobular\\ nodules\\,\\ a\\ mosaic\\ pattern\\ of\\ attenuation\\ \\(air\\ trapping\\)\\,\\ and\\ peribronchial\\ \\(often\\ confluent\\)\\ ground\\ glass\\ opacities\\ are\\ more\\ common\\ and\\ prominent\\ in\\ acute\\ or\\ subacute\\ hp\\ compared\\ to\\ sarcoidosis\\.\\ subacute\\ and\\ acute\\ phase\\ hp\\ preferentially\\ distributes\\ in\\ the\\ lower\\ lobes\\ \\(5\\)\\.\\ it\\ is\\ suggested\\ to\\ use\\ ct\\ to\\ look\\ for\\ concomittent\\ symmetric\\ hilar\\ and\\ medastinal\\ lymph\\ node\\ enlargement\\ or\\ the\\ presence\\ of\\ reticular\\ nodular\\ opacities\\ elsewhere\\ for\\ diagnostic\\ clues\\ \\(1\\)\\.\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ both\\ sarcoidosis\\ and\\ lymphangitic\\ carcinomatosis\\ cause\\ a\\ beaded\\ appearance\\ along\\ the\\ bronchovascular\\ bundles\\.\\ lymphangitic\\ carcinomatosis\\ causes\\ a\\ more\\ marked\\ septal\\ thickening\\ with\\ thickened\\ polygonal\\ lines\\,\\ the\\ hallmark\\ of\\ this\\ disease\\.\\ furthermore\\,\\ with\\ sarcoidosis\\,\\ the\\ nodules\\ typically\\ have\\ irregular\\ margins\\ as\\ those\\ in\\ lymphangitic\\ carcinomatosis\\ have\\ smooth\\ margins\\ \\(5\\)\\.\\ silicosis\\ can\\ be\\ mimicked\\ by\\ sarcoidosis\\ with\\ the\\ formation\\ of\\ conglomerate\\ masses\\ of\\ fibrosis\\ in\\ the\\ upper\\ perihilar\\ regions\\ \\(1\\)\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ \\	\\	\ \(94\)\
\-\ definition\\/background\\:\\ sarcoidosis\\ is\\ a\\ multisystem\\ granulomatous\\ disease\\ characterized\\ histologically\\ by\\ noncaseating\\ granulomas\\ \\(1\\)\\.\\ \ \(0\)\
\-\ \\	\ \(2191\)\
\-\ epidemiology\\:\\ sarcoidosis\\ is\\ more\\ common\\ in\\ blacks\\ than\\ whites\\ and\\ it\\ is\\ rare\\ in\\ asians\\ \\(1\\)\\.\\ sarcoidosis\\ shows\\ a\\ predilection\\ for\\ women\\ with\\ most\\ patients\\ being\\ 20\\-40\\ years\\ old\\ at\\ the\\ time\\ of\\ diagnosis\\ \\(1\\,2\\)\\.\\ in\\ the\\ united\\ states\\,\\ the\\ estimated\\ lifetime\\ incidence\\ of\\ sarcoidosis\\ in\\ african\\ americans\\ is\\ 2\\.4\\%\\ versus\\ 0\\.85\\%\\ in\\ whites\\ \\(2\\)\\.\\ \ \(0\)\
\-\ etiology\\:\\ etiology\\ is\\ unknown\\ \\(2\\)\\.\ \(0\)\
\-\ \\	\ \(2191\)\
\-\ pathogenesis\\:\\ activation\\ of\\ pulmonary\\ macrophages\\ that\\ recruit\\ mononuclear\\ cells\\ leading\\ to\\ the\\ formation\\ of\\ granulomas\\ \\(1\\)\\.\\ the\\ granulomas\\ are\\ a\\ discrete\\ tight\\ collection\\ of\\ noncaseating\\ epitheliod\\ cells\\.\\ the\\ early\\ sarcoidosis\\ reaction\\ is\\ characterized\\ by\\ accumulation\\ of\\ cd45ro\\+\\,\\ t\\ lymphocytes\\,\\ and\\ macrophages\\.\\ an\\ unknown\\ stimulus\\ causing\\ persistent\\ inflammation\\ and\\ accumulation\\ of\\ chemoattractant\\ cytokines\\ to\\ an\\ inflamed\\ area\\ are\\ proposed\\ granuloma\\ formation\\ mechanisms\\ \\(2\\)\\.\\ dense\\ bands\\ of\\ fibroblasts\\,\\ mast\\ cells\\,\\ collagen\\,\\ and\\ proteoglycans\\ may\\ encase\\ the\\ granuloma\\ and\\ lead\\ to\\ fibrosis\\ and\\ irreversible\\ destruction\\ of\\ affected\\ organs\\ \\(5\\)\\.\\ \ \(0\)\
\-\ \\	\ \(2191\)\
\-\ clinical\\ presentation\\:\\ lofgren\\‚\\Ä\\ôs\\ syndrome\\ presents\\ in\\ 20\\%\\-50\\%\\ of\\ all\\ cases\\ of\\ acute\\ disease\\.\\ lofgren\\‚\\Ä\\ôs\\ syndrome\\ presents\\ as\\ pulmonary\\ hilar\\ lymphadenopathy\\,\\ polyarthralgias\\,\\ and\\ erythema\\ nodosum\\.\\ 50\\%\\ of\\ patients\\ receive\\ the\\ diagnosis\\ of\\ sarcoidosis\\ after\\ presenting\\ for\\ chronic\\ cough\\,\\ dyspnea\\ or\\ chest\\ pain\\.\\ delay\\ in\\ diagnosis\\ is\\ often\\ due\\ to\\ the\\ non\\-specific\\ mild\\ nature\\ of\\ early\\ symptoms\\,\\ misdiagnosis\\,\\ and\\ economic\\ barriers\\ to\\ medical\\ care\\.\\ african\\ americans\\ are\\ more\\ likely\\ to\\ have\\ extrathoracic\\ involvement\\ of\\ the\\ bone\\ marrow\\,\\ skin\\,\\ liver\\,\\ and\\ eyes\\ \\(uveitis\\)\\ compared\\ to\\ whites\\.\\ whites\\ are\\ more\\ likely\\ to\\ have\\ hypercalcemia\\ \\(2\\)\\.\\ \\ other\\ laboratory\\ findings\\ include\\ hypergammaglobulinemia\\,\\ elevated\\ serum\\ angiotensin\\-converting\\ enzyme\\ and\\ cutaneous\\ anergy\\ to\\ ppd\\ skin\\ test\\ \\(1\\)\\.\\ \ \(0\)\
\-\ findings\\:\\ 90\\%\\ of\\ patients\\ with\\ sarcoidosis\\ show\\ abnormalities\\ on\\ chest\\ radiographs\\.\\ enlargement\\ of\\ the\\ mediastinal\\ and\\ hilar\\ \\.\\.\\.\\.\\.\\.\\.\\(continued\\)\\ see\\ disease\\ topic\\ 7308\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.44113787694248047\ \(0\)\
\-\ of\\:\\ 0\\.18684077890099948\ \(0\)\
\-\ the\\:\\ 0\\.17896173962619413\ \(0\)\
\-\ and\\:\\ 0\\.1554389140102538\ \(0\)\
\-\ whites\\:\\ 0\\.1504883749386209\ \(0\)\
\-\ lymphangitic\\:\\ 0\\.13466087301372015\ \(0\)\
\-\ hilar\\:\\ 0\\.13264756114415577\ \(0\)\
\-\ to\\:\\ 0\\.1301924583706196\ \(0\)\
\-\ in\\:\\ 0\\.12955165136015726\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.1253380901545073\ \(0\)\
\-\ ct\\:\\ 0\\.12116104171665114\ \(0\)\
\-\ for\\:\\ 0\\.11399741888015194\ \(0\)\
\-\ or\\:\\ 0\\.1107137628153207\ \(0\)\
\-\ chest\\:\\ 0\\.10690200403251196\ \(0\)\
\-\ with\\:\\ 0\\.10197404521192972\ \(0\)\
\-\ granulomas\\:\\ 0\\.09760037861375138\ \(0\)\
\-\ fibrosis\\:\\ 0\\.09694838033085208\ \(0\)\
\-\ lofgren\\:\\ 0\\.0925367643758068\ \(0\)\
\-\ enlargement\\:\\ 0\\.08872248866183162\ \(0\)\
\-\ are\\:\\ 0\\.08782667555437856\ \(0\)\
\-\ glass\\:\\ 0\\.08730941897472255\ \(0\)\
\-\ ground\\:\\ 0\\.08449235487748462\ \(0\)\
\-\ noncaseating\\:\\ 0\\.08324211959996881\ \(0\)\
\-\ hp\\:\\ 0\\.08139269119648442\ \(0\)\
\-\ patients\\:\\ 0\\.08137883724936752\ \(0\)\
\-\ more\\:\\ 0\\.07943349600595158\ \(0\)\
\-\ is\\:\\ 0\\.0792319319930661\ \(0\)\
\-\ irreversible\\:\\ 0\\.07727974536197418\ \(0\)\
\-\ americans\\:\\ 0\\.07727974536197418\ \(0\)\
\-\ hila\\:\\ 0\\.07436156385167224\ \(0\)\
\-\ disease\\:\\ 0\\.07286746440271913\ \(0\)\
\-\ peribronchial\\:\\ 0\\.07279789441673455\ \(0\)\
\-\ macrophages\\:\\ 0\\.07209804642064642\ \(0\)\
\-\ years\\:\\ 0\\.07093943282009789\ \(0\)\
\-\ mediastinal\\:\\ 0\\.0700860736083895\ \(0\)\
\-\ mycobacterial\\:\\ 0\\.06970017242206582\ \(0\)\
\-\ formation\\:\\ 0\\.06881071729357302\ \(0\)\
\-\ perihilar\\:\\ 0\\.06821306012449829\ \(0\)\
\-\ confluent\\:\\ 0\\.06691634747931867\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.06691634747931867\ \(0\)\
\-\ cells\\:\\ 0\\.06687482636498505\ \(0\)\
\-\ superimposed\\:\\ 0\\.06541080870519968\ \(0\)\
\-\ that\\:\\ 0\\.06277676493084339\ \(0\)\
\-\ langerhans\\:\\ 0\\.060731024210622334\ \(0\)\
\-\ diagnosis\\:\\ 0\\.05999233594618266\ \(0\)\
\-\ it\\:\\ 0\\.05923930968478127\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.058035791731022086\ \(0\)\
\-\ have\\:\\ 0\\.05781225354671248\ \(0\)\
\-\ remarkable\\:\\ 0\\.05706898694517589\ \(0\)\
\-\ accumulation\\:\\ 0\\.05590843436520932\ \(0\)\
\-\ opacities\\:\\ 0\\.05524520652641045\ \(0\)\
\-\ clinical\\:\\ 0\\.055007005426771186\ \(0\)\
\-\ subacute\\:\\ 0\\.05415080543487396\ \(0\)\
\-\ characterized\\:\\ 0\\.05316306406254007\ \(0\)\
\-\ pulmonary\\:\\ 0\\.05290595263572262\ \(0\)\
\-\ granuloma\\:\\ 0\\.052359176461574175\ \(0\)\
\-\ african\\:\\ 0\\.05226302623881856\ \(0\)\
\-\ time\\:\\ 0\\.051445973036046866\ \(0\)\
\-\ cell\\:\\ 0\\.04965111310187555\ \(0\)\
\-\ margins\\:\\ 0\\.049368796977077134\ \(0\)\
\-\ lobes\\:\\ 0\\.04827848430305285\ \(0\)\
\-\ atypical\\:\\ 0\\.04747152050113776\ \(0\)\
\-\ acute\\:\\ 0\\.04695313054968463\ \(0\)\
\-\ be\\:\\ 0\\.046946036019917425\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.04677963152668369\ \(0\)\
\-\ compared\\:\\ 0\\.04677963152668369\ \(0\)\
\-\ bilateral\\:\\ 0\\.046647187421546464\ \(0\)\
\-\ etiology\\:\\ 0\\.04661378958937134\ \(0\)\
\-\ infectious\\:\\ 0\\.046559106046955706\ \(0\)\
\-\ features\\:\\ 0\\.046559106046955706\ \(0\)\
\-\ inflammation\\:\\ 0\\.046504715715291564\ \(0\)\
\-\ as\\:\\ 0\\.04649185961348179\ \(0\)\
\-\ upper\\:\\ 0\\.04638225341265289\ \(0\)\
\-\ bronchalveolar\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ shares\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ sarcodosis\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ distributes\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ concomittent\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ medastinal\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ chemoattractant\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ proteoglycans\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ polyarthralgias\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ hypergammaglobulinemia\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ anergy\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ 7308\\:\\ 0\\.0462683821879034\ \(0\)\
\-\ stage\\:\\ 0\\.04607978353059556\ \(0\)\
\-\ nodules\\:\\ 0\\.04597627474926392\ \(0\)\
\-\ from\\:\\ 0\\.045962072135888\ \(0\)\
\-\ ii\\:\\ 0\\.04562209209765335\ \(0\)\
\-\ prominent\\:\\ 0\\.04557248919904537\ \(0\)\
\-\ lymph\\:\\ 0\\.044995436612018026\ \(0\)\
\-\ an\\:\\ 0\\.04425382243093336\ \(0\)\
\-\ peribronchovascular\\:\\ 0\\.04421190927064829\ \(0\)\
\-\ epitheliod\\:\\ 0\\.04421190927064829\ \(0\)\
\-\ stimulus\\:\\ 0\\.04421190927064829\ \(0\)\
\-\ mast\\:\\ 0\\.04421190927064829\ \(0\)\
\-\ nodosum\\:\\ 0\\.04421190927064829\ \(0\)\
\-\ unknown\\:\\ 0\\.04384752582400701\ \(0\)\
\-\ malignancy\\:\\ 0\\.04331887296212165\ \(0\)\
\-\ skin\\:\\ 0\\.04304522859227608\ \(0\)\
\-\ findings\\:\\ 0\\.04283713674918631\ \(0\)\
\-\ discriminate\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ mosaic\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ polygonal\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ conglomerate\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ multisystem\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ asians\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ cytokines\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ economic\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ barriers\\:\\ 0\\.042752818515497316\ \(0\)\
\-\ ago\\:\\ 0\\.042337669632264964\ \(0\)\
\-\ since\\:\\ 0\\.04191495127833991\ \(0\)\
\-\ presents\\:\\ 0\\.04175318989158743\ \(0\)\
\-\ early\\:\\ 0\\.041710019610371935\ \(0\)\
\-\ lch\\:\\ 0\\.04162105979998441\ \(0\)\
\-\ mononuclear\\:\\ 0\\.04162105979998441\ \(0\)\
\-\ misdiagnosis\\:\\ 0\\.04162105979998441\ \(0\)\
\-\ traced\\:\\ 0\\.04069634559824221\ \(0\)\
\-\ aspergilloma\\:\\ 0\\.04069634559824221\ \(0\)\
\-\ mimicked\\:\\ 0\\.04069634559824221\ \(0\)\
\-\ 50\\:\\ 0\\.040410602319781753\ \(0\)\
\-\ was\\:\\ 0\\.04033219308304189\ \(0\)\
\-\ preferentially\\:\\ 0\\.039914510880773364\ \(0\)\
\-\ clues\\:\\ 0\\.039914510880773364\ \(0\)\
\-\ blacks\\:\\ 0\\.039914510880773364\ \(0\)\
\-\ encase\\:\\ 0\\.039914510880773364\ \(0\)\
\-\ uveitis\\:\\ 0\\.039914510880773364\ \(0\)\
\-\ thickening\\:\\ 0\\.039365674878767375\ \(0\)\
\-\ areas\\:\\ 0\\.03928548653586275\ \(0\)\
\-\ activation\\:\\ 0\\.039237254843091235\ \(0\)\
\-\ followed\\:\\ 0\\.0390746992618402\ \(0\)\
\-\ noncalcified\\:\\ 0\\.03863987268098709\ \(0\)\
\-\ lifetime\\:\\ 0\\.03863987268098709\ \(0\)\
\-\ fibroblasts\\:\\ 0\\.03863987268098709\ \(0\)\
\-\ extrathoracic\\:\\ 0\\.03863987268098709\ \(0\)\
\-\ enzyme\\:\\ 0\\.03863987268098709\ \(0\)\
\-\ density\\:\\ 0\\.038369637298763866\ \(0\)\
\-\ beaded\\:\\ 0\\.038105496127578325\ \(0\)\
\-\ often\\:\\ 0\\.03775610594220187\ \(0\)\
\-\ radiograph\\:\\ 0\\.03768764377533466\ \(0\)\
\-\ patient\\:\\ 0\\.03764035876895253\ \(0\)\
\-\ hrct\\:\\ 0\\.03762209373465523\ \(0\)\
\-\ hallmark\\:\\ 0\\.03762209373465523\ \(0\)\
\-\ recruit\\:\\ 0\\.03762209373465523\ \(0\)\
\-\ radiographs\\:\\ 0\\.037529673045810036\ \(0\)\
\-\ 20\\:\\ 0\\.03733011698610365\ \(0\)\
\-\ such\\:\\ 0\\.0372209256997748\ \(0\)\
\-\ centrilobular\\:\\ 0\\.03718078192583612\ \(0\)\
\-\ bronchovascular\\:\\ 0\\.03718078192583612\ \(0\)\
\-\ image\\:\\ 0\\.03700600722498594\ \(0\)\
\-\ by\\:\\ 0\\.03685846870292648\ \(0\)\
\-\ cts\\:\\ 0\\.03604902321032321\ \(0\)\
\-\ see\\:\\ 0\\.03599483481707137\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.03572169117068515\ \(0\)\
\-\ epidemiology\\:\\ 0\\.03572169117068515\ \(0\)\
\-\ 10mm\\:\\ 0\\.03541420998330004\ \(0\)\
\-\ histologically\\:\\ 0\\.03541420998330004\ \(0\)\
\-\ lung\\:\\ 0\\.035199199777281115\ \(0\)\
\-\ bundles\\:\\ 0\\.035124309008581\ \(0\)\
\-\ infection\\:\\ 0\\.03495306497065128\ \(0\)\
\-\ syndrome\\:\\ 0\\.03488382393352775\ \(0\)\
\-\ tight\\:\\ 0\\.03485008621103291\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0346114915355081\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.034589932455172244\ \(0\)\
\-\ elsewhere\\:\\ 0\\.034589932455172244\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.034589932455172244\ \(0\)\
\-\ inflamed\\:\\ 0\\.034589932455172244\ \(0\)\
\-\ likely\\:\\ 0\\.03457795837256591\ \(0\)\
\-\ all\\:\\ 0\\.03444492338309289\ \(0\)\
\-\ came\\:\\ 0\\.03434247429111216\ \(0\)\
\-\ silicosis\\:\\ 0\\.03434247429111216\ \(0\)\
\-\ mechanisms\\:\\ 0\\.03434247429111216\ \(0\)\
\-\ fissures\\:\\ 0\\.034106530062249146\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.03388107577771725\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.033458173739659335\ \(0\)\
\-\ adenomatous\\:\\ 0\\.033458173739659335\ \(0\)\
\-\ indications\\:\\ 0\\.033458173739659335\ \(0\)\
\-\ predilection\\:\\ 0\\.033458173739659335\ \(0\)\
\-\ proposed\\:\\ 0\\.033458173739659335\ \(0\)\
\-\ reticular\\:\\ 0\\.033067836091325895\ \(0\)\
\-\ trapping\\:\\ 0\\.032883383535961194\ \(0\)\
\-\ ppd\\:\\ 0\\.032883383535961194\ \(0\)\
\-\ common\\:\\ 0\\.032815385063767834\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.03253345953791713\ \(0\)\
\-\ both\\:\\ 0\\.03226767997110305\ \(0\)\
\-\ predominance\\:\\ 0\\.03205005714499403\ \(0\)\
\-\ united\\:\\ 0\\.03160874533617493\ \(0\)\
\-\ furthermore\\:\\ 0\\.031469780855010746\ \(0\)\
\-\ established\\:\\ 0\\.031202777825622856\ \(0\)\
\-\ follow\\:\\ 0\\.031193596452942566\ \(0\)\
\-\ 1998\\:\\ 0\\.03107436878276616\ \(0\)\
\-\ selected\\:\\ 0\\.03107436878276616\ \(0\)\
\-\ 5mm\\:\\ 0\\.03082691061870608\ \(0\)\
\-\ reasons\\:\\ 0\\.030707566611821283\ \(0\)\
\-\ bands\\:\\ 0\\.030707566611821283\ \(0\)\
\-\ distortion\\:\\ 0\\.03059096638984306\ \(0\)\
\-\ receive\\:\\ 0\\.030476986620662012\ \(0\)\
\-\ can\\:\\ 0\\.03036507308382073\ \(0\)\
\-\ bronchiectasis\\:\\ 0\\.03025643507819976\ \(0\)\
\-\ ensure\\:\\ 0\\.030149654581023953\ \(0\)\
\-\ detection\\:\\ 0\\.030149654581023953\ \(0\)\
\-\ usual\\:\\ 0\\.03004507590123724\ \(0\)\
\-\ estimated\\:\\ 0\\.03004507590123724\ \(0\)\
\-\ cutaneous\\:\\ 0\\.03004507590123724\ \(0\)\
\-\ discrete\\:\\ 0\\.02994261006725325\ \(0\)\
\-\ organs\\:\\ 0\\.02984217339363884\ \(0\)\
\-\ this\\:\\ 0\\.029824549851068534\ \(0\)\
\-\ bronchial\\:\\ 0\\.029459207674330152\ \(0\)\
\-\ collagen\\:\\ 0\\.029367819863555113\ \(0\)\
\-\ stability\\:\\ 0\\.029189840680193754\ \(0\)\
\-\ may\\:\\ 0\\.029118873366635423\ \(0\)\
\-\ look\\:\\ 0\\.02910313965824085\ \(0\)\
\-\ lines\\:\\ 0\\.028851589613139054\ \(0\)\
\-\ up\\:\\ 0\\.028623026374488537\ \(0\)\
\-\ but\\:\\ 0\\.02861372442743393\ \(0\)\
\-\ institution\\:\\ 0\\.028611928354958977\ \(0\)\
\-\ emphysema\\:\\ 0\\.028383082638487874\ \(0\)\
\-\ pericardial\\:\\ 0\\.02830903918805605\ \(0\)\
\-\ no\\:\\ 0\\.028224959127671388\ \(0\)\
\-\ patchy\\:\\ 0\\.028164118292494874\ \(0\)\
\-\ impression\\:\\ 0\\.028164118292494874\ \(0\)\
\-\ septal\\:\\ 0\\.028164118292494874\ \(0\)\
\-\ eyes\\:\\ 0\\.028093181663768844\ \(0\)\
\-\ topic\\:\\ 0\\.027687214153216778\ \(0\)\
\-\ suspicion\\:\\ 0\\.027495799501664697\ \(0\)\
\-\ helpful\\:\\ 0\\.02743356698744168\ \(0\)\
\-\ suggested\\:\\ 0\\.02707540271743698\ \(0\)\
\-\ order\\:\\ 0\\.026740871405793676\ \(0\)\
\-\ 46\\:\\ 0\\.026581532031270037\ \(0\)\
\-\ delay\\:\\ 0\\.026529512228831154\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.026376579448350233\ \(0\)\
\-\ destruction\\:\\ 0\\.026376579448350233\ \(0\)\
\-\ interstitial\\:\\ 0\\.026228123398065805\ \(0\)\
\-\ erythema\\:\\ 0\\.026179588230787088\ \(0\)\
\-\ women\\:\\ 0\\.026036708746513728\ \(0\)\
\-\ parenchymal\\:\\ 0\\.025989962919975428\ \(0\)\
\-\ serum\\:\\ 0\\.02594364400192407\ \(0\)\
\-\ mediastinum\\:\\ 0\\.025897744265349545\ \(0\)\
\-\ fungal\\:\\ 0\\.025897744265349545\ \(0\)\
\-\ part\\:\\ 0\\.025852256191149028\ \(0\)\
\-\ lead\\:\\ 0\\.025762485948965633\ \(0\)\
\-\ granulomatous\\:\\ 0\\.025718189717392172\ \(0\)\
\-\ leading\\:\\ 0\\.025718189717392172\ \(0\)\
\-\ versus\\:\\ 0\\.02558757598583477\ \(0\)\
\-\ nature\\:\\ 0\\.025544775003763915\ \(0\)\
\-\ dense\\:\\ 0\\.02550233219310496\ \(0\)\
\-\ dyspnea\\:\\ 0\\.025460241609000973\ \(0\)\
\-\ states\\:\\ 0\\.025418497453384946\ \(0\)\
\-\ discussion\\:\\ 0\\.02533602594073297\ \(0\)\
\-\ improvement\\:\\ 0\\.025254874029044885\ \(0\)\
\-\ opacity\\:\\ 0\\.025175000153466905\ \(0\)\
\-\ scans\\:\\ 0\\.025175000153466905\ \(0\)\
\-\ iii\\:\\ 0\\.024980651231496787\ \(0\)\
\-\ incidence\\:\\ 0\\.02490495003100082\ \(0\)\
\-\ node\\:\\ 0\\.02486751896608179\ \(0\)\
\-\ regions\\:\\ 0\\.024830362123880578\ \(0\)\
\-\ 32\\:\\ 0\\.024793475515649966\ \(0\)\
\-\ symmetric\\:\\ 0\\.024793475515649966\ \(0\)\
\-\ phase\\:\\ 0\\.02475685523904313\ \(0\)\
\-\ those\\:\\ 0\\.02475685523904313\ \(0\)\
\-\ reaction\\:\\ 0\\.024612962289629798\ \(0\)\
\-\ nodes\\:\\ 0\\.02457761799136276\ \(0\)\
\-\ distribution\\:\\ 0\\.024542518292274763\ \(0\)\
\-\ thickened\\:\\ 0\\.02440449926479514\ \(0\)\
\-\ displaced\\:\\ 0\\.024171650480810693\ \(0\)\
\-\ until\\:\\ 0\\.024075040202154164\ \(0\)\
\-\ clinically\\:\\ 0\\.024043241437953992\ \(0\)\
\-\ marrow\\:\\ 0\\.024043241437953992\ \(0\)\
\-\ smooth\\:\\ 0\\.023887171084668958\ \(0\)\
\-\ affected\\:\\ 0\\.023795783273893912\ \(0\)\
\-\ causing\\:\\ 0\\.023765682970258627\ \(0\)\
\-\ absent\\:\\ 0\\.02373576025056888\ \(0\)\
\-\ continued\\:\\ 0\\.023706013031710518\ \(0\)\
\-\ foci\\:\\ 0\\.023647036945384992\ \(0\)\
\-\ relatively\\:\\ 0\\.023559839045030895\ \(0\)\
\-\ suggestive\\:\\ 0\\.023559839045030895\ \(0\)\
\-\ test\\:\\ 0\\.023531103068579654\ \(0\)\
\-\ 27\\:\\ 0\\.023445859275849846\ \(0\)\
\-\ collection\\:\\ 0\\.02336202453612983\ \(0\)\
\-\ diameter\\:\\ 0\\.023252357857645782\ \(0\)\
\-\ outside\\:\\ 0\\.023225307733387598\ \(0\)\
\-\ increase\\:\\ 0\\.023225307733387598\ \(0\)\
\-\ 90\\:\\ 0\\.023118527236211786\ \(0\)\
\-\ nodular\\:\\ 0\\.02303989176529778\ \(0\)\
\-\ there\\:\\ 0\\.023023814297088458\ \(0\)\
\-\ us\\:\\ 0\\.02301394855642507\ \(0\)\
\-\ recommended\\:\\ 0\\.02301394855642507\ \(0\)\
\-\ nodule\\:\\ 0\\.022835969373063716\ \(0\)\
\-\ pneumonia\\:\\ 0\\.022835969373063716\ \(0\)\
\-\ presenting\\:\\ 0\\.02266402455838101\ \(0\)\
\-\ additional\\:\\ 0\\.022428080329517985\ \(0\)\
\-\ irregular\\:\\ 0\\.022336692518742943\ \(0\)\
\-\ persistent\\:\\ 0\\.022291608788328355\ \(0\)\
\-\ complications\\:\\ 0\\.02215871333538159\ \(0\)\
\-\ attenuation\\:\\ 0\\.022136898737123645\ \(0\)\
\-\ use\\:\\ 0\\.022136898737123645\ \(0\)\
\-\ diagnostic\\:\\ 0\\.022050566673544027\ \(0\)\
\-\ marked\\:\\ 0\\.02188218984091216\ \(0\)\
\-\ causes\\:\\ 0\\.021861530397780483\ \(0\)\
\-\ at\\:\\ 0\\.021855878268212583\ \(0\)\
\-\ rare\\:\\ 0\\.021840954766007482\ \(0\)\
\-\ process\\:\\ 0\\.021699216185186488\ \(0\)\
\-\ pattern\\:\\ 0\\.02160034587547462\ \(0\)\
\-\ cough\\:\\ 0\\.02160034587547462\ \(0\)\
\-\ cardiac\\:\\ 0\\.021484190731490285\ \(0\)\
\-\ effusion\\:\\ 0\\.021484190731490285\ \(0\)\
\-\ active\\:\\ 0\\.021484190731490285\ \(0\)\
\-\ radiographic\\:\\ 0\\.0214650875590907\ \(0\)\
\-\ lungs\\:\\ 0\\.021351955293675708\ \(0\)\
\-\ abnormality\\:\\ 0\\.021044474106290588\ \(0\)\
\-\ laboratory\\:\\ 0\\.02100949544160884\ \(0\)\
\-\ abnormalities\\:\\ 0\\.020957475639169956\ \(0\)\
\-\ involvement\\:\\ 0\\.020940253597915775\ \(0\)\
\-\ above\\:\\ 0\\.02087194433269182\ \(0\)\
\-\ presence\\:\\ 0\\.02078783152140858\ \(0\)\
\-\ middle\\:\\ 0\\.020688703552813978\ \(0\)\
\-\ care\\:\\ 0\\.020672368961316197\ \(0\)\
\-\ typically\\:\\ 0\\.02031049960949276\ \(0\)\
\-\ because\\:\\ 0\\.020220196578162798\ \(0\)\
\-\ being\\:\\ 0\\.020160875594603035\ \(0\)\
\-\ liver\\:\\ 0\\.019958551310373687\ \(0\)\
\-\ presentation\\:\\ 0\\.01991622656175634\ \(0\)\
\-\ enlarged\\:\\ 0\\.01972325108967306\ \(0\)\
\-\ elevated\\:\\ 0\\.01972325108967306\ \(0\)\
\-\ cause\\:\\ 0\\.019709744060981513\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.019696272907574412\ \(0\)\
\-\ although\\:\\ 0\\.019696272907574412\ \(0\)\
\-\ masses\\:\\ 0\\.019696272907574412\ \(0\)\
\-\ cases\\:\\ 0\\.019459717202880148\ \(0\)\
\-\ along\\:\\ 0\\.019383255157622698\ \(0\)\
\-\ right\\:\\ 0\\.019184233744088234\ \(0\)\
\-\ vascular\\:\\ 0\\.019100385774597113\ \(0\)\
\-\ finding\\:\\ 0\\.019017335488714576\ \(0\)\
\-\ several\\:\\ 0\\.018982154633602928\ \(0\)\
\-\ air\\:\\ 0\\.018924056790136312\ \(0\)\
\-\ differential\\:\\ 0\\.018798536887930855\ \(0\)\
\-\ area\\:\\ 0\\.018742493375422855\ \(0\)\
\-\ medical\\:\\ 0\\.01838737010857278\ \(0\)\
\-\ show\\:\\ 0\\.018366626168506078\ \(0\)\
\-\ some\\:\\ 0\\.018203659979656908\ \(0\)\
\-\ year\\:\\ 0\\.017832474513071846\ \(0\)\
\-\ demonstrated\\:\\ 0\\.01778075794159899\ \(0\)\
\-\ on\\:\\ 0\\.017475851598275378\ \(0\)\
\-\ appearance\\:\\ 0\\.017441911966763875\ \(0\)\
\-\ abnormal\\:\\ 0\\.01738188894343884\ \(0\)\
\-\ lymphoma\\:\\ 0\\.017230728826671232\ \(0\)\
\-\ she\\:\\ 0\\.017222461691546447\ \(0\)\
\-\ include\\:\\ 0\\.01721420800986149\ \(0\)\
\-\ chronic\\:\\ 0\\.017173139880407893\ \(0\)\
\-\ scan\\:\\ 0\\.017164966008733656\ \(0\)\
\-\ old\\:\\ 0\\.017125348396791022\ \(0\)\
\-\ performed\\:\\ 0\\.01711619749571746\ \(0\)\
\-\ shows\\:\\ 0\\.01698051345336896\ \(0\)\
\-\ presented\\:\\ 0\\.016871436426257557\ \(0\)\
\-\ been\\:\\ 0\\.016856043739856788\ \(0\)\
\-\ lobe\\:\\ 0\\.016719572198667158\ \(0\)\
\-\ due\\:\\ 0\\.016630589455324894\ \(0\)\
\-\ one\\:\\ 0\\.01656486214746245\ \(0\)\
\-\ than\\:\\ 0\\.016400662889350257\ \(0\)\
\-\ mild\\:\\ 0\\.016400662889350257\ \(0\)\
\-\ symptoms\\:\\ 0\\.015829888431131985\ \(0\)\
\-\ bone\\:\\ 0\\.015786138062581827\ \(0\)\
\-\ consistent\\:\\ 0\\.015687532064416317\ \(0\)\
\-\ noted\\:\\ 0\\.015339642925487252\ \(0\)\
\-\ most\\:\\ 0\\.015057028917343288\ \(0\)\
\-\ other\\:\\ 0\\.015024792243504318\ \(0\)\
\-\ lower\\:\\ 0\\.014784224710209752\ \(0\)\
\-\ contrast\\:\\ 0\\.014057412080157126\ \(0\)\
\-\ after\\:\\ 0\\.014035331565195198\ \(0\)\
\-\ well\\:\\ 0\\.014008961213192983\ \(0\)\
\-\ female\\:\\ 0\\.013960968812919557\ \(0\)\
\-\ has\\:\\ 0\\.013215241944532307\ \(0\)\
\-\ normal\\:\\ 0\\.011812694542855162\ \(0\)\
\-\ not\\:\\ 0\\.011421619877738041\ \(0\)\
\-\ pain\\:\\ 0\\.010352893091104402\ \(0\)\
